Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Letter Commentary & Co-Mentions | Period / Date | Action |
|---|---|---|---|
“Our best performing stocks were in Healthcare, where Dechra Pharmaceuticals, a UK veterinarian drug maker, was propelled by an offer to take it private, and Abcam, a global leader in life sciences research tools, is reviewing potential takeover inquiries.” | Q2 2023 Jun 30, 2023 | Preview | |
“Our best performing stocks were in Healthcare, where Dechra Pharmaceuticals, a UK veterinarian drug maker, was propelled by an offer to take it private, and Abcam, a global leader in life sciences research tools, is reviewing potential takeover inquiries.” | Q2 2023 Jun 30, 2023 | Preview |
Read unredacted commentary excerpts, portfolio weight disclosures, and high-conviction theses from hedge fund managers discussing $DPH.L.
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
